A Study to Investigate the Safety and Tolerability of TE-8105 in Overweight/Obese Participants Without Diabetes

NCT06471530 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight and Obesity

Interventions

DRUG: TE-8105 SAD Cohort 1
DRUG: TE-8105 SAD Cohort 3
DRUG: TE-8105 SAD Cohort 5 (Adaptive cohort)
DRUG: TE-8105 MAD Cohort 1
DRUG: TE-8105 MAD Cohort 2
DRUG: TE-8105 SAD Cohort 2
DRUG: TE-8105 SAD Cohort 4

Sponsor

Immunwork, Inc.